No Data Yet
A StockStory analysis on December 17, 2025, recommends buying Oscar Health (OSCR) due to its 39.7% annual revenue growth, while advising to sell Amtech (ASYS) and Rockwell Automation (ROK) following sales and profit declines.
Oscar Health stock rallied on Wednesday, December 17, while competitors Centene and HCA Healthcare declined following a Republican announcement that could block the extension of ACA subsidies.
Congress has failed to extend enhanced Affordable Care Act (ACA) premium subsidies, which are set to expire on December 31. This legislative inaction creates significant uncertainty for health insurers like Centene and for the 24 million Americans enrolled in ACA marketplace plans, who now face steep premium increases.
Oscar Health (OSCR) stock surged approximately 35% on reports of a potential two-year extension of Affordable Care Act (ACA) subsidies. However, the health-tech insurer faces significant headwinds from analyst downgrades, continued unprofitability, and substantial policy uncertainty, creating a sharp division among investors.